The Organoid group at the Hubrecht Institute have identified a new link between FBXW7 mutations and EGFR signaling activity. The FBXW7 gene is commonly mutated in colorectal cancer and such mutations ...
The RAMOSE and RELAY trials revealed the capacity and constraints of combination therapy with ramucirumab (Cyramza) in EGFR-mutated metastatic non-small cell lung cancer (NSCLC). The phase II RAMOSE ...
The epidermal growth factor receptor (EGFR) inhibitors are among the most intensely studied new molecular therapeutic agents. Although response rates have been somewhat disappointing when EGFR ...
Initial data from a phase 2 (NCT05256290) clinical trial show that silevertinib yields robust antitumor activity and ...
Human epidermal growth factor receptor 2 (HER2) is a membrane-spanning receptor that belongs to the family of epidermal growth factor receptor tyrosine kinases (EGFR TKIs), which consists of three ...
For the purpose of clarity, the signaling pathways can be discussed in isolation. However, in reality there is considerable cross-talk between pathways, with parallel or upstream input from other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback